Overview

ABT-751 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Status:
Terminated
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as ABT-751, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase I/II trial is studying the side effects and best dose of ABT-751 and to see how well it works in treating patients with metastatic prostate cancer that did not respond to hormone therapy.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Vanderbilt-Ingram Cancer Center
Collaborator:
National Cancer Institute (NCI)